Mechanisms of tumour resistance against chemotherapeutic agents in veterinary oncology

Veterinary Journal

Volumn 207, Issue , 2016, Pages 63-72

  Klopfleisch, R ^a   Kohn, B ^a   Gruber, A D ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Apoptosis; Cancer stem cells; Chemotherapy; DNA repair; Epigenetics; Epithelial mesenchymal transition; Oncology; Resistance

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; BIRICODAR; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; GENISTEIN; IMATINIB; IRINOTECAN; LOMUSTINE; MASITINIB; METHOTREXATE; MITOXANTRONE; NAVELBINE; PACLITAXEL; PREDNISONE; PROCARBAZINE; QUININE; SILDENAFIL; TOCERANIB; TOPOTECAN; UNINDEXED DRUG; VARDENAFIL; VINBLASTINE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; DISEASE FREE INTERVAL; DNA CROSS LINKING; DNA REPAIR; DNA SYNTHESIS INHIBITION; DOG DISEASE; DRUG INACTIVATION; DRUG TRANSPORT; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; LYMPHOMA; MISMATCH REPAIR; NONHUMAN; PROTEIN TARGETING; REVIEW; TUMOR ESCAPE; TUMOR RESISTANCE; VETERINARY MEDICINE; VETERINARY ONCOLOGY; ANIMAL; DRUG RESISTANCE; GENETICS; HUMAN; NEOPLASMS; PET ANIMAL; VETERINARY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PETS;

EID: 84952879098     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2015.06.015     Document Type: Review

References (131)

1. Aberdein D., Munday J.S., Howe L., French A.F., Gibson I.R. Widespread mismatch repair expression in feline small intestinal lymphomas. Journal of Comparative Pathology 2012, 147:24-30.
2. Achanta S., Maxwell L.K. Reaction phenotyping of vinblastine metabolism in dogs. Veterinary and Comparative Oncology 2014, 10.1111/vco.12084.
3. Alagoz M., Gilbert D.C., El-Khamisy S., Chalmers A.J. DNA repair and resistance to topoisomerase I inhibitors: Mechanisms, biomarkers and therapeutic targets. Current Medicinal Chemistry 2012, 19:3874-3885.
4. Amagai Y., Tanaka A., Matsuda A., Oida K., Jung K., Nishikawa S., Jang H., Ishizaka S., Matsuda H. Increased expression of the antiapoptotic protein MCL1 in canine mast cell tumors. The Journal of Veterinary Medical Science 2013, 75:971-974.
5. Arlt A., Gehrz A., Muerkoster S., Vorndamm J., Kruse M.L., Folsch U.R., Schafer H. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003, 22:3243-3251.
6. Bach P., Abel T., Hoffmann C., Gal Z., Braun G., Voelker I., Ball C.R., Johnston I.C., Lauer U.M., Herold-Mende C., et al. Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. Cancer Research 2013, 73:865-874.
7. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
8. Bardenheuer W., Lehmberg K., Rattmann I., Brueckner A., Schneider A., Sorg U.R., Seeber S., Moritz T., Flasshove M. Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells. Leukemia 2005, 19:2281-2288.
9. Baumann M., Krause M., Hill R. Exploring the role of cancer stem cells in radioresistance. Nature Reviews. Cancer 2008, 8:545-554.
10. Beretta G.L., Gatti L., Perego P., Zaffaroni N. Camptothecin resistance in cancer: Insights into the molecular mechanisms of a DNA-damaging drug. Current Medicinal Chemistry 2013, 20:1541-1565.
11. Bertolini G., Roz L., Perego P., Tortoreto M., Fontanella E., Gatti L., Pratesi G., Fabbri A., Andriani F., Tinelli S., et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:16281-16286.
12. Bouwman P., Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nature Reviews Cancer 2012, 12:587-598.
13. Brenn S.H., Couto S.S., Craft D.M., Leung C., Bergman P.J. Evaluation of P-glycoprotein expression in feline lymphoma and correlation with clinical outcome. Veterinary and Comparative Oncology 2008, 6:201-211.
14. Brown R., Curry E., Magnani L., Wilhelm-Benartzi C.S., Borley J. Poised epigenetic states and acquired drug resistance in cancer. Nature Reviews Cancer 2014, 14:747-753.
15. Byers L.A., Diao L., Wang J., Saintigny P., Girard L., Peyton M., Shen L., Fan Y., Giri U., Tumula P.K., et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clinical Cancer Research 2013, 19:279-290.
16. Cai J., Damaraju V.L., Groulx N., Mowles D., Peng Y., Robins M.J., Cass C.E., Gros P. Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. Cancer Research 2008, 68:2349-2357.
17. Chien W.W., Le Beux C., Rachinel N., Julien M., Lacroix C.E., Allas S., Sahakian P., Cornut-Thibaut A., Lionnard L., Kucharczak J., et al. Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines. Scientific Reports 2015, 5:8068.
18. Choi Y.H., Yu A.M. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Current Pharmaceutical Design 2014, 20:793-807.
19. Chu X.Y., Kato Y., Niinuma K., Sudo K.I., Hakusui H., Sugiyama Y. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. The Journal of Pharmacology and Experimental Therapeutics 1997, 281:304-314.
20. Colak S., Medema J.P. Cancer stem cells - important players in tumor therapy resistance. The FEBS Journal 2014, 281:4779-4791.
21. Colak S., Zimberlin C.D., Fessler E., Hogdal L., Prasetyanti P.R., Grandela C.M., Letai A., Medema J.P. Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells. Cell Death and Differentiation 2014, 21:1170-1177.
22. Dawood S., Austin L., Cristofanilli M. Cancer stem cells: Implications for cancer therapy. Oncology 2014, 28.
23. Dhaliwal R.S., Kitchell B.E., Ehrhart E., Valli V.E., Dervisis N.G. Clinicopathologic significance of histologic grade, pgp, and p53 expression in canine lymphoma. Journal of the American Animal Hospital Association 2013, 49:175-184.
24. Dincer Z., Jasani B., Haywood S., Mullins J.E., Fuentealba I.C. Metallothionein expression in canine and feline mammary and melanotic tumours. Journal of Comparative Pathology 2001, 125:130-136.
25. Duncan A.W., Rattis F.M., DiMascio L.N., Congdon K.L., Pazianos G., Zhao C., Yoon K., Cook J.M., Willert K., Gaiano N., et al. Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nature Immunology 2005, 6:314-322.
26. Edwards S.L., Brough R., Lord C.J., Natrajan R., Vatcheva R., Levine D.A., Boyd J., Reis-Filho J.S., Ashworth A. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008, 451:1111-1115.
27. Enoch T., Norbury C. Cellular responses to DNA damage: Cell-cycle checkpoints, apoptosis and the roles of p53 and ATM. Trends in Biochemical Sciences 1995, 20:426-430.
28. Erginsoy S.D., Sozmen M., Caldin M., Furlanello T. Metallothionein expression in benign and malignant canine mammary gland tumours. Research in Veterinary Science 2006, 81:46-50.
29. Fan X., Khaki L., Zhu T.S., Soules M.E., Talsma C.E., Gul N., Koh C., Zhang J., Li Y.M., Maciaczyk J., et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010, 28:5-16.
30. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
31. Fernando R.I., Castillo M.D., Litzinger M., Hamilton D.H., Palena C. IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Research 2011, 71:5296-5306.
32. Fink D., Aebi S., Howell S.B. The role of DNA mismatch repair in drug resistance. Clinical Cancer Research 1998, 4:1-6.
33. Fosmire S.P., Thomas R., Jubala C.M., Wojcieszyn J.W., Valli V.E., Getzy D.M., Smith T.L., Gardner L.A., Ritt M.G., Bell J.S., et al. Inactivation of the p16 cyclin-dependent kinase inhibitor in high-grade canine non-Hodgkin's T-cell lymphoma. Veterinary Pathology 2007, 44:467-478.
34. Fu D.R., Kato D., Watabe A., Endo Y., Kadosawa T. Prognostic utility of apoptosis index, Ki-67 and survivin expression in dogs with nasal carcinoma treated with orthovoltage radiation therapy. The Journal of Veterinary Medical Science 2014, 76:1505-1512.
35. Fuchs B.C., Fujii T., Dorfman J.D., Goodwin J.M., Zhu A.X., Lanuti M., Tanabe K.K. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Research 2008, 68:2391-2399.
36. Fujiwara-Igarashi A., Goto-Koshino Y., Mochizuki H., Sato M., Fujino Y., Ohno K., Tsujimoto H. Inhibition of p16 tumor suppressor gene expression via promoter hypermethylation in canine lymphoid tumor cells. Research in Veterinary Science 2014, 97:60-63.
37. Fujiwara-Igarashi A., Goto-Koshino Y., Sato M., Maeda S., Igarashi H., Takahashi M., Fujino Y., Ohno K., Tsujimoto H. Prognostic significance of the expression levels of the p16, p15, and p14 genes in dogs with high-grade lymphoma. The Veterinary Journal 2014, 199:236-244.
38. Ginestier C., Liu S., Diebel M.E., Korkaya H., Luo M., Brown M., Wicinski J., Cabaud O., Charafe-Jauffret E., Birnbaum D., et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. The Journal of Clinical Investigation 2010, 120:485-497.
39. Ginn J., Sacco J., Wong Y.Y., Motsinger-Reif A., Chun R., Trepanier L.A. Positive association between a glutathione-S-transferase polymorphism and lymphoma in dogs. Veterinary and Comparative Oncology 2014, 12:227-236.
40. Glasspool R.M., Brown R., Gore M.E., Rustin G.J., McNeish I.A., Wilson R.H., Pledge S., Paul J., Mackean M., Hall G.D., et al. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. British Journal of Cancer 2014, 110:1923-1929.
41. Goff D.J., Court Recart A., Sadarangani A., Chun H.J., Barrett C.L., Krajewska M., Leu H., Low-Marchelli J., Ma W., Shih A.Y., et al. A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell 2013, 12:316-328.
42. Goldstein L.J., Galski H., Fojo A., Willingham M., Lai S.L., Gazdar A., Pirker R., Green A., Crist W., Brodeur G.M., et al. Expression of a multidrug resistance gene in human cancers. Journal of the National Cancer Institute 1989, 81:116-124.
43. Gramer I., Kessler M., Geyer J. Determination of MDR1 gene expression for prediction of chemotherapy tolerance and treatment outcome in dogs with lymphoma. Veterinary and Comparative Oncology 2013, 10.1111/vco.12051.
44. Grosse N., van Loon B., Rohrer Bley C. DNA damage response and DNA repair - dog as a model?. BMC Cancer 2014, 14:203.
45. Hahn K.A., Barnhill M.A., Freeman K.P., Shoieb A.M. Detection and clinical significance of plasma glutathione-S-transferases in dogs with lymphoma. In Vivo 1999, 13:173-175.
46. Hahn N.M., Bonney P.L., Dhawan D., Jones D.R., Balch C., Guo Z., Hartman-Frey C., Fang F., Parker H.G., Kwon E.M., et al. Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: A novel epigenetic approach to human urothelial carcinoma drug development. The Journal of Urology 2012, 187:302-309.
47. Halsey C.H., Gustafson D.L., Rose B.J., Wolf-Ringwall A., Burnett R.C., Duval D.L., Avery A.C., Thamm D.H. Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia(R)) in canine mast cell tumor. BMC Veterinary Research 2014, 10:105.
48. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
49. He X.C., Zhang J., Tong W.G., Tawfik O., Ross J., Scoville D.H., Tian Q., Zeng X., He X., Wiedemann L.M., et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. Nature Genetics 2004, 36:1117-1121.
50. Hifumi T., Miyoshi N., Kawaguchi H., Nomura K., Yasuda N. Immunohistochemical detection of proteins associated with multidrug resistance to anti-cancer drugs in canine and feline primary pulmonary carcinoma. The Journal of Veterinary Medical Science 2010, 72:665-668.
51. Hoey T., Yen W.C., Axelrod F., Basi J., Donigian L., Dylla S., Fitch-Bruhns M., Lazetic S., Park I.K., Sato A., et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009, 5:168-177.
52. Holohan C., Van Schaeybroeck S., Longley D.B., Johnston P.G. Cancer drug resistance: An evolving paradigm. Nature Reviews Cancer 2013, 13:714-726.
53. Honscha K.U., Schirmer A., Reischauer A., Schoon H.A., Einspanier A., Gabel G. Expression of ABC-transport proteins in canine mammary cancer: Consequences for chemotherapy. Reproduction in Domestic Animals 2009, 44(Suppl. 2):218-223.
54. Housman G., Byler S., Heerboth S., Lapinska K., Longacre M., Snyder N., Sarkar S. Drug resistance in cancer: An overview. Cancers 2014, 6:1769-1792.
55. Huang S., Holzel M., Knijnenburg T., Schlicker A., Roepman P., McDermott U., Garnett M., Grernrum W., Sun C., Prahallad A., et al. MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling. Cell 2012, 151:937-950.
56. Karotki A.V., Vasak M. Reaction of human metallothionein-3 with cisplatin and transplatin. Journal of Biological Inorganic Chemistry 2009, 14:1129-1138.
57. Kathawala R.J., Gupta P., Ashby C.R., Chen Z.S. The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade. Drug Resistance Updates 2015, 18C:1-17.
58. Kavallaris M., Tait A.S., Walsh B.J., He L., Horwitz S.B., Norris M.D., Haber M. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Research 2001, 61:5803-5809.
59. Kemper K., Rodermond H., Colak S., Grandela C., Medema J.P. Targeting colorectal cancer stem cells with inducible caspase-9. Apoptosis 2012, 17:528-537.
60. Klopfleisch R. Personalised medicine in veterinary oncology: One to cure just one. The Veterinary Journal 2015, 205:128-135.
61. Klopfleisch R., Gruber A.D. Increased expression of BRCA2 and RAD51 in lymph node metastases of canine mammary adenocarcinomas. Veterinary Pathology 2009, 46:416-422.
62. Klopfleisch R., Klose P., Gruber A.D. The combined expression pattern of BMP2, LTBP4, and DERL1 discriminates malignant from benign canine mammary tumors. Veterinary Pathology 2010, 47:446-454.
63. Klopfleisch R., Lenze D., Hummel M., Gruber A.D. The metastatic cascade is reflected in the transcriptome of metastatic canine mammary carcinomas. The Veterinary Journal 2011, 190:236-243.
64. Klopfleisch R., von Euler H., Sarli G., Pinho S.S., Gartner F., Gruber A.D. Molecular carcinogenesis of canine mammary tumors: News from an old disease. Veterinary Pathology 2011, 48:98-116.
65. Klopfleisch R., Meyer A., Schlieben P., Bondzio A., Weise C., Lenze D., Hummel M., Einspanier R., Gruber A.D. Transcriptome and proteome analysis of tyrosine kinase inhibitor treated canine mast cell tumour cells identifies potentially kit signaling-dependent genes. BMC Veterinary Research 2012, 8:96.
66. Klose P., Weise C., Bondzio A., Multhaup G., Einspanier R., Gruber A.D., Klopfleisch R. Is there a malignant progression associated with a linear change in protein expression levels from normal canine mammary gland to metastatic mammary tumors?. Journal of Proteome Research 2011, 10:4405-4415.
67. Kobayashi M., Kuroki S., Tanaka Y., Moriya Y., Kozutumi Y., Uehara Y., Ono K., Tamura K., Washizu T., Bonkobara M. Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c.1523A>T mutation. European Journal of Haematology 2015, 10.1111/ejh.12526.
68. Konopleva M., Contractor R., Tsao T., Samudio I., Ruvolo P.P., Kitada S., Deng X., Zhai D., Shi Y.X., Sneed T., et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006, 10:375-388.
69. Krol M., Pawlowski K.M., Majchrzak K., Mucha J., Motyl T. Canine mammary carcinoma cell line are resistant to chemosensitizers: Verapamil and cyclosporin A. Polish Journal of Veterinary Sciences 2014, 17:9-17.
70. Kumaraguruparan R., Subapriya R., Balachandran C., Manohar B.M., Thangadurai A., Nagini S. Xenobiotic-metabolizing enzymes in canine mammary tumours. The Veterinary Journal 2006, 172:364-368.
71. Kwon H.C., Roh M.S., Oh S.Y., Kim S.H., Kim M.C., Kim J.S., Kim H.J. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Annals of Oncology 2007, 18:504-509.
72. Lai K., Kaspar B.K., Gage F.H., Schaffer D.V. Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo. Nature Neuroscience 2003, 6:21-27.
73. Liu S., Ginestier C., Ou S.J., Clouthier S.G., Patel S.H., Monville F., Korkaya H., Heath A., Dutcher J., Kleer C.G., et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Research 2011, 71:614-624.
74. Lombardo Y., Scopelliti A., Cammareri P., Todaro M., Iovino F., Ricci-Vitiani L., Gulotta G., Dieli F., de Maria R., Stassi G. Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology 2011, 140:297-309.
75. London C.A. Kinase dysfunction and kinase inhibitors. Veterinary Dermatology 2013, 24:181-187.
76. Lowenberg B., van Putten W., Theobald M., Gmur J., Verdonck L., Sonneveld P., Fey M., Schouten H., de Greef G., Ferrant A., et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. The New England Journal of Medicine 2003, 349:743-752.
77. Martano M., Carella F., Squillacioti C., Restucci B., Mazzotta M., Lo Muzio L., Maiolino P. Metallothionein expression in canine cutaneous apocrine gland tumors. Anticancer Research 2012, 32:747-752.
78. Martin S.A., McCarthy A., Barber L.J., Burgess D.J., Parry S., Lord C.J., Ashworth A. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Molecular Medicine 2009, 1:323-337.
79. Meijer C., Mulder N.H., Timmer-Bosscha H., Sluiter W.J., Meersma G.J., de Vries E.G. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Research 1992, 52:6885-6889.
80. Mhaidat N.M., Alali F.Q., Matalqah S.M., Matalka I.I., Jaradat S.A., Al-Sawalha N.A., Thorne R.F. Inhibition of MEK sensitizes paclitaxel-induced apoptosis of human colorectal cancer cells by downregulation of GRP78. Anti-Cancer Drugs 2009, 20:601-606.
81. Michael M., Doherty M.M. Tumoral drug metabolism: Overview and its implications for cancer therapy. Journal of Clinical Oncology 2005, 23:205-229.
82. Mirmohammadsadegh A., Mota R., Gustrau A., Hassan M., Nambiar S., Marini A., Bojar H., Tannapfel A., Hengge U.R. ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis. The Journal of Investigative Dermatology 2007, 127:2207-2215.
83. Miyashita T., Reed J.C. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Research 1992, 52:5407-5411.
84. Munday J.S., French A.F., Gibson I.R., Gwynne K. Widespread mismatch repair protein expression in canine cutaneous mast cell tumors. Veterinary Pathology 2009, 46:227-232.
85. Nakaichi M., Takeshita Y., Okuda M., Nakamoto Y., Itamoto K., Une S., Sasaki N., Kadosawa T., Takahashi T., Taura Y. Expression of the MDR1 gene and P-glycoprotein in canine mast cell tumor cell lines. The Journal of Veterinary Medical Science 2007, 69:111-115.
86. Nebbioso A., Carafa V., Benedetti R., Altucci L. Trials with 'epigenetic' drugs: An update. Molecular Oncology 2012, 6:657-682.
87. Nieto A., Perez-Alenza M.D., Del Castillo N., Tabanera E., Castano M., Pena L. BRCA1 expression in canine mammary dysplasias and tumours: Relationship with prognostic variables. Journal of Comparative Pathology 2003, 128:260-268.
88. Nobili S., Landini I., Mazzei T., Mini E. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Medicinal Research Reviews 2012, 32:1220-1262.
89. Noguchi K., Katayama K., Sugimoto Y. Human ABC transporter ABCG2/BCRP expression in chemoresistance: Basic and clinical perspectives for molecular cancer therapeutics. Pharmacogenomics and Personalized Medicine 2014, 7:53-64.
90. Okai Y., Nakamura N., Matsushiro H., Kato H., Setoguchi A., Yazawa M., Okuda M., Watari T., Hasegawa A., Tsujimoto H. Molecular analysis of multidrug resistance in feline lymphoma cells. American Journal of Veterinary Research 2000, 61:1122-1127.
91. Pabst T., Vellenga E., van Putten W., Schouten H.C., Graux C., Vekemans M.C., Biemond B., Sonneveld P., Passweg J., Verdonck L., et al. Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. Blood 2012, 119:5367-5373.
92. Pang L.Y., Argyle D.J. The evolving cancer stem cell paradigm: Implications in veterinary oncology. The Veterinary Journal 2015, 205:154-160.
93. Pang L.Y., Blacking T.M., Else R.W., Sherman A., Sang H.M., Whitelaw B.A., Hupp T.R., Argyle D.J. Feline mammary carcinoma stem cells are tumorigenic, radioresistant, chemoresistant and defective in activation of the ATM/p53 DNA damage pathway. The Veterinary Journal 2013, 196:414-423.
94. Pang L.Y., Argyle S.A., Kamida A., Morrison K.O., Argyle D.J. The long-acting COX-2 inhibitor mavacoxib (Trocoxil) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro. BMC Veterinary Research 2014, 10:184.
95. Pavet V., Portal M.M., Moulin J.C., Herbrecht R., Gronemeyer H. Towards novel paradigms for cancer therapy. Oncogene 2011, 30:1-20.
96. Pawlak A., Rapak A., Zbyryt I., Obminska-Mrukowicz B. The effect of common antineoplastic agents on induction of apoptosis in canine lymphoma and leukemia cell lines. In Vivo 2014, 28:843-850.
97. Pawlowski K.M., Mucha J., Majchrzak K., Motyl T., Krol M. Expression and role of PGP, BCRP, MRP1 and MRP3 in multidrug resistance of canine mammary cancer cells. BMC Veterinary Research 2013, 9:119.
98. Perez E.A. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Molecular Cancer Therapeutics 2009, 8:2086-2095.
99. Piovan E., Yu J., Tosello V., Herranz D., Ambesi-Impiombato A., Da Silva A.C., Sanchez-Martin M., Perez-Garcia A., Rigo I., Castillo M., et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell 2013, 24:766-776.
100. Qiu M., Peng Q., Jiang I., Carroll C., Han G., Rymer I., Lippincott J., Zachwieja J., Gajiwala K., Kraynov E., et al. Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells. Cancer Letters 2013, 328:261-270.
101. Rabik C.A., Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treatment Reviews 2007, 33:9-23.
102. Rebhun R.B., Lana S.E., Ehrhart E.J., Charles J.B., Thamm D.H. Comparative analysis of survivin expression in untreated and relapsed canine lymphoma. Journal of Veterinary Internal Medicine 2008, 22:989-995.
103. Rocha T.A., Mauldin G.N., Patnaik A.K., Bergman P.J. Prognostic factors in dogs with urinary bladder carcinoma. Journal of Veterinary Internal Medicine 2000, 14:486-490.
104. Saez-Ayala M., Fernandez-Perez M.P., Montenegro M.F., Sanchez-del-Campo L., Chazarra S., Pinero-Madrona A., Cabezas-Herrera J., Rodriguez-Lopez J.N. Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance. Experimental Cell Research 2012, 318:1146-1159.
105. Sarkaria J.N., Kitange G.J., James C.D., Plummer R., Calvert H., Weller M., Wick W. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clinical Cancer Research 2008, 14:2900-2908.
106. Schlossmacher G., Stevens A., White A. Glucocorticoid receptor-mediated apoptosis: Mechanisms of resistance in cancer cells. The Journal of Endocrinology 2011, 211:17-25.
107. Shoieb A.M., Hahn K.A., Van Laack R.L., Barnhill M.A. In vitro reversal of glutathione-S-transferase-mediated resistance in canine osteosarcoma (COS31) cells. In Vivo 1998, 12:455-462.
108. Signore M., Pelacchi F., di Martino S., Runci D., Biffoni M., Giannetti S., Morgante L., De Majo M., Petricoin E.F., Stancato L., et al. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. Cell Death and Disease 2014, 5:e1223.
109. Simon D., Moreno S.N., Hirschberger J., Moritz A., Kohn B., Neumann S., Jurina K., Scharvogel S., Schwedes C., Reinacher M., et al. Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma. Journal of the American Veterinary Medical Association 2008, 232:879-885.
110. Smallwood T.L., Small G.W., Suter S.E., Richards K.L. Expression of asparagine synthetase predicts in vitro response to L-asparaginase in canine lymphoid cell lines. Leukemia and Lymphoma 2014, 55:1357-1365.
111. Sugimoto Y., Tsukahara S., Oh-hara T., Isoe T., Tsuruo T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Research 1990, 50:6925-6930.
112. Swaminathan S.K., Roger E., Toti U., Niu L., Ohlfest J.R., Panyam J. CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. Journal of Controlled Release 2013, 171:280-287.
113. Takahashi-Yanaga F., Kahn M. Targeting Wnt signaling: Can we safely eradicate cancer stem cells?. Clinical Cancer Research 2010, 16:3153-3162.
114. Tang J., Xie X., Zhang X., Qiao X., Jiang S., Shi W., Shao Y., Zhou X. Long term cultured HL-60 cells are intrinsically resistant to Ara-C through high CDA activity. Frontiers in Bioscience 2012, 17:569-574.
115. Thamm D.H., Grunerud K.K., Rose B.J., Vail D.M., Bailey S.M. DNA repair deficiency as a susceptibility marker for spontaneous lymphoma in golden retriever dogs: A case-control study. PLoS ONE 2013, 8. e69192.
116. Thayanithy V., Park C., Sarver A.L., Kartha R.V., Korpela D.M., Graef A.J., Steer C.J., Modiano J.F., Subramanian S. Combinatorial treatment of DNA and chromatin-modifying drugs cause cell death in human and canine osteosarcoma cell lines. PLoS ONE 2012, 7. e43720.
117. Tomiyasu H., Goto-Koshino Y., Takahashi M., Fujino Y., Ohno K., Tsujimoto H. Quantitative analysis of mRNA for 10 different drug resistance factors in dogs with lymphoma. The Journal of Veterinary Medical Science 2010, 72:1165-1172.
118. Tomiyasu H., Fujiwara-Igarashi A., Goto-Koshino Y., Fujino Y., Ohno K., Tsujimoto H. Evaluation of DNA methylation profiles of the CpG island of the ABCB1 gene in dogs with lymphoma. American Journal of Veterinary Research 2014, 75:835-841.
119. Tomiyasu H., Goto-Koshino Y., Fujino Y., Ohno K., Tsujimoto H. Antitumour effect and modulation of expression of the ABCB1 gene by perifosine in canine lymphoid tumour cell lines. The Veterinary Journal 2014, 201:83-90.
120. Tomiyasu H., Goto-Koshino Y., Fujino Y., Ohno K., Tsujimoto H. Epigenetic regulation of the ABCB1 gene in drug-sensitive and drug-resistant lymphoid tumour cell lines obtained from canine patients. The Veterinary Journal 2014, 199:103-109.
121. Tomiyasu H., Goto-Koshino Y., Fujino Y., Ohno K., Tsujimoto H. The regulation of the expression of ABCG2 gene through mitogen-activated protein kinase pathways in canine lymphoid tumor cell lines. The Journal of Veterinary Medical Science 2014, 76:237-242.
122. van Steensel B. Chromatin: Constructing the big picture. The EMBO Journal 2011, 30:1885-1895.
123. Van der Heyden S., Chiers K., Vercauteren G., Daminet S., Wegge B., Paepe D., Ducatelle R. Expression of multidrug resistance-associated P-glycoprotein in feline tumours. Journal of Comparative Pathology 2011, 144:164-169.
124. Wilting R.H., Dannenberg J.H. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resistance Updates 2012, 15:21-38.
125. Yang Z., Zhu W., Gao S., Yin T., Jiang W., Hu M. Breast cancer resistance protein (ABCG2) determines distribution of genistein phase II metabolites: Reevaluation of the roles of ABCG2 in the disposition of genistein. Drug Metabolism and Disposition 2012, 40:1883-1893.
126. Yoshimoto K., Ma X., Guan Y., Mizoguchi M., Nakamizo A., Amano T., Hata N., Kuga D., Sasaki T. Expression of stem cell marker and receptor kinase genes in glioblastoma tissue quantified by real-time RT-PCR. Brain Tumor Pathology 2011, 28:291-296.
127. Zandvliet M., Teske E., Chapuis T., Fink-Gremmels J., Schrickx J.A. Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein. Journal of Veterinary Pharmacology and Therapeutics 2013, 36:583-587.
128. Zandvliet M., Teske E., Schrickx J.A. Multi-drug resistance in a canine lymphoid cell line due to increased P-glycoprotein expression, a potential model for drug-resistant canine lymphoma. Toxicology in Vitro 2014, 28:1498-1506.
129. Zandvliet M., Teske E., Schrickx J.A., Mol J.A. A longitudinal study of ABC transporter expression in canine multicentric lymphoma. The Veterinary Journal 2015, 205:263-271.
130. Zhang N., Yin Y., Xu S.J., Chen W.S. 5-Fluorouracil: Mechanisms of resistance and reversal strategies. Molecules 2008, 13:1551-1569.
131. Zhao C., Chen A., Jamieson C.H., Fereshteh M., Abrahamsson A., Blum J., Kwon H.Y., Kim J., Chute J.P., Rizzieri D., et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009, 458:776-779.